The Identification of Three Novel Biomarkers of Major Adverse Kidney Events

Abstract

Aim

To describe the prognostic value of three novel biomarkers for acute adverse kidney events compared with routine biological markers.

Material & methods

We used high-end MS to quantify biomarkers predictive of acute kidney injury (AKI) and major adverse kidney events (MAKE) in 100 adult patients after open heart surgery (n = 100).

Results

Early postoperatively measured LG3 (a C-terminal fragment of perlecan), LTBP2 (latent transforming growth factor binding protein-2), Cathepsin L as well as two other renal biomarkers (NGAL, Cystatin C) had greater predictive value for AKI (n = 23) and MAKE (n = 24) compared with creatinine, urea and urine output.

Conclusions

LG3, LTBP2 and Cathepsin L deserve further exploration as biomarkers for the early identification of patients at risk of MAKE.

Keywords::

• C-terminal fragment of perlecan
• cathepsin L
• creatinine
• cystatin C
• latent transforming growth factor binding protein-2
• LG3
• LTBP2
• major adverse kidney event
• MAKE
• neutrophil gelatinase-associated lipocalin
• NGAL
• urea
• urine output

Financial & competing interests disclosure

M Haase has received lecture fees and travel cost reimbursements from Abbott Diagnostics, Astute Medical and Alere, with all companies involved in the development of renal biomarkers. G Thomas, G Vanpoucke, W Laroy and K Verleysen are employees of Pronota NV (Belgium), a company which is involved in the development of renal biomarkers. This study was also funded by grants from the German Heart Foundation (Deutsche Stiftung fuer Herzforschung, Frankfurt a. M., Germany) and the Else Kroener-Fresenius-Stiftung (Bad Homburg, Germany). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

M Haase has received lecture fees and travel cost reimbursements from Abbott Diagnostics, Astute Medical and Alere, with all companies involved in the development of renal biomarkers. G Thomas, G Vanpoucke, W Laroy and K Verleysen are employees of Pronota NV (Belgium), a company which is involved in the development of renal biomarkers. This study was also funded by grants from the German Heart Foundation (Deutsche Stiftung fuer Herzforschung, Frankfurt a. M., Germany) and the Else Kroener-Fresenius-Stiftung (Bad Homburg, Germany). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.